A vision: In silico clinical trials without patients

Ogilvie，Lesley A.1,2; Rieke，Damian T.3,4; Lehrach，Hans1,2,5,6

2020

Digital twin In silico trials Molecular models

英语

The development of the technology required to generate (molecular) digital twins provides the technological basis for in silico clinical trials, as well as major virtualization of many other steps in the drug development process, offering the potential of orders of magnitude reductions in the cost of bringing new drugs to the market, and a corresponding increase in new drugs in many disease areas, including those for which risks have been considered too high to justify commercial development. The same basic technology will, however, also be used to truly personalize therapy choice and preventive and wellness measures, further increasing health and well-being worldwide.

10.1016/B978-0-12-824490-6.00020-7

Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic

39-48

其他

2-s2.0-85126397546

Scopus

1.Alacris Theranostics GmbH,Berlin,Germany
2.Max Planck Institute for Molecular Genetics,Berlin,Germany
3.Charité Comprehensive Cancer Centre,Charité - Universitätsmedizin Berlin,Berlin,Germany
4.Berlin Institute of Health,Berlin,Germany
5.Dahlem Centre for Genome Research and Medical Systems Biology,Berlin,Germany
6.Southern University of Science and Technology,Shenzhen,Guangdong,China

Ogilvie，Lesley A.,Rieke，Damian T.,Lehrach，Hans. A vision: In silico clinical trials without patients. 2020-01-01.